Flovent HFA Sales Data
| Rank 58 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Flovent HFA U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 58 ( 11) |
$263,072 | 13.97% | 1,678 | 7.77% |
| Q3 2013 | 69 ( 15) |
$230,829 | -9.90% | 1,557 | -11.73% |
| Q2 2013 | 54 (1) |
$256,187 | -3.99% | 1,764 | -7.50% |
| Q1 2013 | 53 (6) |
$266,820 | -0.67% | 1,907 | -2.80% |
| Q4 2012 | 47 (15) |
$268,626 | 13.24% | 1,962 | 12.95% |
| Q3 2012 | 62 (1) |
$237,214 | -2.46% | 1,737 | -1.59% |
| Q2 2012 | 61 (5) |
$243,193 | 0.68% | 1,765 | -6.61% |
| Q1 2012 | 66 (1) |
$241,552 | -1.45% | 1,890 | -1.66% |
| Q4 2011 | 67 (5) |
$245,114 | 15.06% | 1,922 | 16.13% |
| Q3 2011 | 72 (3) |
$213,037 | -10.26% | 1,655 | -9.36% |
| Q2 2011 | 69 (5) |
$237,395 | -3.77% | 1,826 | -4.60% |
| Q1 2011 | 64 | $246,705 | n/a | 1,914 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
